Review Article | By Z.A. Ali; P.W. Serruys; G.W. Stone et al
BACKGROUND - Bioresorbable vascular scaffolds (BVS) offer the potential to improve long-term outcomes of percutaneous coronary intervention after their complete bioresorption. Randomised trials have shown non-inferiority between BVS and metallic drug-eluting stents at 1 year in composite safety and effectiveness outcomes, although some increases in rates of target vessel-related myocardial infarction and device throm...
Clinical Trial | By Z Ge, ZZ Liu, SL Chen et al.
Type 2 diabetes correlates with clinical events after the implantation of a second-generation drug-eluting stent (DES). The rate and prognostic value of stent fracture (SF) in patients with diabetes who underwent DES implantation remain unknown. A total of 1160 patients with- and 2251 without- diabetes, who underwent surveillance angiography at 1 year after DES implantation between June 2004 and August 2014, were prospectively studied. ...
Clinical Trial | By P Andell, S Karlsson, M.A.Mohammad et al.
CONCLUSIONS - IVUS was associated with an independent and significant outcome benefit when performing unprotected LMCA PCI. Potential mediators of this benefit include larger and more appropriately sized stents, perhaps translating into lower risk of subsequent stent thrombosis. Although residual confounding cannot be ruled out, our findings indicate a possible hazard when performing unprotected LMCA PC...
Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Metallic Stents
Review Article | By S Sorrentino , G Giustino, GD Dangas et al
Background - Recent evidence suggests that bioresorbable vascular scaffolds (BVS) are associated with an excess of thrombotic complications compared with metallic everolimus-eluting stents (EES). Objectives - This study sought to investigate the comparative effectiveness of the Food and Drug Administration-approved BVS versus metallic EES in patients undergoing percutaneous coronary intervention at longest available foll...
Cardiac Sympathetic Denervation for Refractory Ventricular Arrhythmias
Clinical Trial | By M. Vaseghi, K. Shivkumar, et al
Background - Cardiac sympathetic denervation (CSD) has been shown to reduce the burden of implantable cardioverter-defibrillator (ICD) shocks in small series of patients with structural heart disease (SHD) and recurrent ventricular tachyarrhythmias (VT). Objectives - This study assessed the value of CSD and the characteristics associated with outcomes in this population. Methods - P...
Review Article | By T Palmerini, LB Reggiani, GW Stone et al.
BACKGROUND - Although some randomized controlled trials (RCTs) and meta-analyses have suggested that prolonged dual-antiplatelet therapy (DAPT) may be associated with increased mortality, the mechanistic underpinnings of this association remain unclear. METHODS - RCTs comparing different DAPT durations after drug-eluting stent placement were sought through the MEDLINE, Embase, and Cochrane databases a...
Current Interventions for the Left Main Bifurcation
Review Article | By Rab T, Sheiban I, Louvard Y et al
Contemporary clinical trials, registries, and meta-analyses, supported by recent results from the EXCEL (Everolimus-Eluting Stents or Bypass Surgery for Left Main Coronary Artery Disease) and NOBLE (Percutaneous Coronary Angioplasty Versus Coronary Artery Bypass Grafting in Treatment of Unprotected Left Main Stenosis) trials, have established percutaneous coronary intervention of left main coronary stenosis as a safe alternative to c...
Clinical Trial | By E. A. Secemsky; R.W. Yeh; D.J. Kereiakes et al
Objective - To assess the prognosis of cardiovascular and bleeding events occurring beyond 1 year after coronary stenting. Exposures - Ischemic events (myocardial infarction not related to stent thrombosis, stent thrombosis, and ischemic stroke) and bleeding events (Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries [GUSTO] classification moderate or severe bleeding). Results - In total, 25 682 individua...